Skip To Main Content
Madeleine Johnson on Muck Rack

Madeleine Johnson

Verified
New York
As seen in: 360Dx, GenomeWeb, Financial Times, Entrepreneur, Slate, Boing Boing, Crain's Chicago Business, Modern Healthcare, Valley News, Spectrum, Vinson & Elkins, BYU-I Scroll and
MA journalism/PhD neuroscience. Science writer. Tricoteuse, but with crochet. NTA.

Get in touch with Madeleine

Contact Madeleine, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Madeleine Johnson’s Journalist Portfolio

See all →
The Disease That May Have Killed the Pilgrims' Neighbors Is Still a Threat

The Disease That May Have Killed the Pilgrims' Neighbors Is Still a Threat

It's quite possible that America as we know it would not exist without rat urine and leptospirosis, the disea…

View article →
The taste of victory

The taste of victory

An award-winning gustatory neuroscientist is using his discoveries to overcome a total aversion to fruits and…

View article →
Lavender and Old Lace

Lavender and Old Lace

To calm agitated dementia patients some caregivers are turning away from sedatives and toward aromatherapy

View article →
Spaying, Neutering, and the Mental Health of Cats and Dogs

Spaying, Neutering, and the Mental Health of Cats and Dogs

Could spaying and neutering cause behavioral problems in pets? There are good biological to suspect this migh…

View article →
Feeding the mosquitoes

Feeding the mosquitoes

In the quest to prevent mosquito-borne illness, Leslie Vosshall must first feed 500 hungry bugs a blood meal.…

View article →
Can a heat wave make you insane?

Can a heat wave make you insane?

People act crazy when it is hot outside. Why?

View article →

Articles

Siemens Healthineers Ups FY26 EPS Guidance, Lowers Revenue Outlook on Tariff Refunds, Dx Decline

|
By Madeleine Johnson Verified
| 360Dx Verified
NEW YORK – Siemens Healthineers on Friday raised its earnings expectations for fiscal 2026 in light of tariff refunds but lowered its overall revenue outlook due in part to declining revenue in the diagnostics business. The firm said its fiscal third quarter revenues increased 2 percent as reported or 3 percent on a comparable basis, with growth in imaging and precision therapy offset by a 6 percent decline in diagnostics.
Open in Who Shared Issue with article?

En Carta Diagnostics Advances 'Frugal' Design for Lyme Disease At-Home MDx Original

|
By Madeleine Johnson Verified
| 360Dx Verified
NEW YORK – Targeting a low-cost and strategic market entry for its aptamer and isothermal amplification-based infectious disease testing platform, En Carta Diagnostics is working on launching a Lyme disease test, its first at-home molecular test, by the end of 2027. The Paris-based firm won breakthrough device designation for the test earlier this year from the US Food and Drug Administration and secured €5 million ($5.7 million) in private financing earlier this month.
Open in Who Shared View Duplicates (2) Issue with article?

Ibex Medical Analytics Gets CE-IVDR for Breast Cancer IHCs

|
By Madeleine Johnson Verified
| 360Dx Verified
NEW YORK – Ibex Medical Analytics announced on Thursday that it has obtained CE marking under the EU's In Vitro Diagnostic Regulation for its Ibex Breast estrogen receptor (ER), progesterone receptor (PR) and Ki67 artificial intelligence-powered immunohistochemistry and digital pathology tests.
Open in Who Shared Issue with article?
See all 571 articles